These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22691900)

  • 21. Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
    Lewin AJ; Kereiakes DJ; Chrysant SG; Izzo JL; Oparil S; Lee J; Fernandez V; Melino M
    Ethn Dis; 2014; 24(1):41-7. PubMed ID: 24620447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
    Kereiakes DJ; Neutel J
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):285-93. PubMed ID: 20801941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.
    Neutel JM; Kereiakes DJ;
    Am J Cardiovasc Drugs; 2010; 10(5):289-303. PubMed ID: 20712386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
    Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
    Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
    Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
    J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
    Nesbitt SD; Shojaee A; Maa JF; Weir MR
    J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
    Kereiakes DJ; Chrysant SG; Izzo JL; Littlejohn T; Melino M; Lee J; Fernandez V; Heyrman R
    Cardiovasc Diabetol; 2012 Oct; 11():134. PubMed ID: 23110471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy.
    Punzi H; Shojaee A; Maa JF;
    Ther Adv Cardiovasc Dis; 2012 Aug; 6(4):149-61. PubMed ID: 22855062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy.
    Zhu JR; Zhang SY; Gao PJ
    Arch Pharm Res; 2014 Dec; 37(12):1588-98. PubMed ID: 25060946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes.
    Neutel JM; Kereiakes DJ; Waverczak WF; Stoakes KA; Xu J; Shojaee A
    Curr Med Res Opin; 2010 Mar; 26(3):721-8. PubMed ID: 20085534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
    Chrysant SG; Littlejohn T; Izzo JL; Kereiakes DJ; Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):233-43. PubMed ID: 22799613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
    Heagerty AM; Mallion JM
    Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.
    Omboni S; Malacco E; Mallion JM; Volpe M; Zanchetti A;
    J Hypertens; 2012 Jul; 30(7):1468-77. PubMed ID: 22573127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.